Vironova to co-develop unique virus and nanoparticle analysis equipment in a €1,72 million EU granted project

Vironova today announces grant funding from the EU for a €1,72 million Eurostars^TM project - “MiniTEM” - aiming at developing the world’s first portable transmission electron microscope for identification of viruses and characterization of other biological nanoparticles. The project was ranked nr 2 out of 110 qualified applications from companies and Universities around Europe within diverse applications and industries.

MiniTEM is a collaborative project between Vironova AB (publ), DELONG INSTRUMENTS a.s. and the Centre for Image Analysis (CBA), part of Uppsala University and Swedish University for Agricultural Sciences. The members of the consortium are leading actors within their respective field and together they provide a unique approach to rapid, automated and cost efficient virus diagnostics and nanoparticle characterization through miniaturized transmission electron microscope (TEM) and image analysis technology. The products to be developed during the coming three years – address the two large and fast growing global markets of virus diagnostics and nanomedicine related research and development. The prospective customers are primarily pharmaceutical companies, hospitals and Universities world-wide which seek improved solutions to new and currently unmet needs.

“Yet again Vironova has received international recognition for its groundbreaking technology and innovative image analysis solutions within TEM products”, says C.E.O Mohammed Homman and continues, “and more importantly, the financial support from the EU will help us accelerate the time-to-market for our new products with significant sales potential”.

About Eurostars

The Eurostars Programme (“Eurostars”) is a European innovation programme. Its purpose is to provide funding for market-oriented research and development with the active participation of research and development - performing small - and medium-sized enterprises. Eurostars is a joint initiative between EUREKA and the EU Seventh Framework Programme for Research and Technological Development (FP7).

Contact

For further information please contact: Mr Mohammed Homman, C.E.O or Dr. Heather Marshall-Heyman, MiniTEM project coordinator. Tel: +46 (0)8-702 67 90

About Vironova

Vironova AB (publ) is a Swedish biotech company dedicated to the development of novel antiviral therapeutics and virus diagnostics solutions to combat viral diseases. With a new virus safety laboratory and proprietary technology to analyze nano-sized particles in digital images acquired by electron microscopy, Vironova also serves the biopharmaceutical industry with tools to assess and optimize R&D and production processes – from discovery and optimization stage through preclinical and clinical phase II. Read more about Vironova at the website www.vironova.com.